热景生物预计2025年净利亏损2.1亿元至2.3亿元

Core Viewpoint - The company, Hotgen Biotech (688068), is forecasting a net profit loss of between 210 million to 230 million yuan for the year 2025, indicating an increase in losses of 9.94% to 20.42% compared to the previous year [2] Industry Impact - The in vitro diagnostic industry is facing significant challenges due to industry policies such as centralized procurement, leading to a short-term decline in domestic prices and reduced demand [2] - Adjustments in national tax policies for the industry have had a considerable impact on the company's overall gross margin and profits [2] Asset Impairment - The company has adhered to its consistent impairment policy, resulting in the recognition of asset impairment losses related to its reagents and equipment [2]